Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study to examines the impact of anifrolumab on disease activity, immune phenotypes, and
development of neutralizing antibodies to quadrivalent influenza vaccine in patients with
Systemic Lupus Erythematosus (SLE). 10 patients with moderately to severely active SLE will
be treated with anifrolumab in addition to standard of care lupus treatments and 10 will
receive only standard of care medications. All will receive influenza vaccine.
Phase:
Early Phase 1
Details
Lead Sponsor:
Oklahoma Medical Research Foundation
Collaborators:
Columbia University NYU Langone Health Piedmont Heart Institute, Inc., Atlanta, GA Yale University